<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 19:23:22[mciao0826] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<header>
<title>Dapoxetine</title>
<id>2190486</id>
<revision>
<id>231067612</id>
<timestamp>2008-08-10T18:48:48Z</timestamp>
<contributor>
<username>DumZiBoT</username>
<id>6085301</id>
</contributor>
</revision>
<categories>
<category>Urology</category>
</categories>
</header>
<bdy>

<table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" width="280" align="right" cellpadding="1" class="toccolours" border="0">

<row>
<col colspan="2" align="center">
 <image width="150px" src="Dapoxetine-2D-skeletal.png">
<caption>

 220px 
</caption>
</image>
</col>
</row>
<row>
<col colspan="2" align="center">
Dapoxetine</col>
</row>
<row>
<col colspan="2" align="center" bgcolor="#dddddd">
 <b>Systematic (<link xlink:type="simple" xlink:href="../503/3141503.xml">
IUPAC</link>) name</b></col>
</row>
<row>
<col colspan="2" style="text-align: center; vertical-align: top;" bgcolor="#eeeeee">
(1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenyl-propan-1-amine</col>
</row>






<row>
<col colspan="2" bgcolor="#dddddd">
<b>Identifiers</b></col>
</row>
<row>
<col width="90" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../815/160815.xml">
CAS number</link></col>
<col bgcolor="#eeeeee">
 <weblink xlink:type="simple" xlink:href="http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?term=119356-77-3&amp;rn=1">
119356-77-3</weblink>&#32;129938-20-1 (HCl salt)</col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../770/2770.xml">
ATC code</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col bgcolor="#ddeeff">
 <institute wordnetid="108407330" confidence="0.8">
<association wordnetid="108049401" confidence="0.8">
<link xlink:type="simple" xlink:href="../723/2863723.xml">
PubChem</link></association>
</institute>
</col>
<col bgcolor="#eeeeee">
 <weblink xlink:type="simple" xlink:href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71353">
71353</weblink></col>
</row>

<row>
<col colspan="2" bgcolor="#dddddd">
<b>Chemical data</b></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../043/7043.xml">
Formula</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../836/19836.xml">
Mol. mass</link></col>
<col bgcolor="#eeeeee">
305.413 g/mol</col>
</row>









<row>
<col colspan="2" bgcolor="#dddddd">
<b>Pharmacokinetic data</b></col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../021/769021.xml">
Bioavailability</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../475/1173475.xml">
Metabolism</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../099/3206099.xml">
Half life</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../468/255468.xml">
Excretion</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col colspan="2" bgcolor="#dddddd">
<b>Therapeutic considerations</b></col>
</row>

<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../622/588622.xml">
Pregnancy cat.</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../840/1186840.xml">
Legal status</link></col>
<col bgcolor="#eeeeee">
℞ Prescription only</col>
</row>

<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <work wordnetid="100575741" confidence="0.8">
<treatment wordnetid="100658082" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<care wordnetid="100654885" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<activity wordnetid="100407535" confidence="0.8">
<link xlink:type="simple" xlink:href="../816/334816.xml">
Routes</link></activity>
</psychological_feature>
</act>
</care>
</event>
</treatment>
</work>
</col>
<col bgcolor="#eeeeee">
Oral</col>
</row>
</table>

<b>Dapoxetine</b> is the <link xlink:type="simple" xlink:href="../768/611768.xml">
International Nonproprietary Name</link> of a short-acting <link xlink:type="simple" xlink:href="../581/29581.xml">
SSRI</link> drug<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref> currently being considered for approval by the <link xlink:type="simple" xlink:href="../632/11632.xml">
Food and Drug Administration</link> (FDA) for the treatment of <link xlink:type="simple" xlink:href="../103/292103.xml">
premature ejaculation</link> in men, which would make it the first drug approved for such treatment.  It is currently in Phase III of the approval process.  
<sec>
<st>
Function</st>
<p>

If approved, this would make Dapoxetine join the ranks of <link xlink:type="simple" xlink:href="../783/14783.xml">
erectile dysfunction</link> drugs such as <link xlink:type="simple" xlink:href="../565/32565.xml">
sildenafil</link> (Viagra), <link xlink:type="simple" xlink:href="../271/382271.xml">
tadalafil</link> (Cialis), and <link xlink:type="simple" xlink:href="../250/649250.xml">
vardenafil</link> (Levitra), and some dopamine agonists such as <link xlink:type="simple" xlink:href="../706/1435706.xml">
cabergoline</link> (Dostinex) and <link xlink:type="simple" xlink:href="../386/3987386.xml">
pramipexole</link>, as drugs which can be used to improve male <link xlink:type="simple" xlink:href="../778/2159778.xml">
sexual health</link>. Misuse of these drugs as <link xlink:type="simple" xlink:href="../705/70705.xml">
aphrodisiacs</link> or sexual enhancers in individuals who do not suffer from sexual health problems is also a possibility and there have been some concerns about doctors being pressured to prescribe such drugs off-label to people who do not actually have a medical need for the drug. </p>
<p>

Some research has shown Dapoxetine to have a benefit in the treatment of premature ejaculation.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref></p>

</sec>
<sec>
<st>
Approval process</st>
<p>

Dapoxetine was created by <link xlink:type="simple" xlink:href="../905/758905.xml">
Eli Lilly and Company</link> and is credited to biochemist David T. Wong. Originally known as LY 210448, it was being developed by Lilly as an antidepressant.  Eli Lilly sold the patent to <company wordnetid="108058098" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../826/166826.xml">
Johnson &amp; Johnson</link></company>
 for $65 million dollars and future royalties in December 2003.</p>
<p>

Dapoxetine was submitted to the FDA in the form of dapoxetine hydrochloride by the <link xlink:type="simple" xlink:href="../040/684040.xml">
ALZA Corporation</link> and its parent company, Johnson &amp; Johnson for the treatment of premature ejaculation with a New Drug Application (NDA) to the Food and Drug Administration (FDA) on December 28, 2004.</p>
<p>

In October 2005, the FDA issued a "not approvable" letter for dapoxetine.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%223%22])">3</ref></p>
<p>

Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks.</p>
<p>

Dapoxetine was submitted for approval in Europe and is now being reviewed.</p>

</sec>
<sec>
<st>
References</st>

<p>

<reflist>
<entry id="1">
 <cite style="font-style:normal">Kendirci M, Salem E, Hellstrom WJ&#32;(June 2007).&#32;"Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation". <it>Ther Clin Risk Manag</it>&#32;<b>3</b>&#32;(2): 277–89. PMID 18360636.</cite>&nbsp;</entry>
<entry id="2">
 <cite style="font-style:normal">Safarinejad MR&#32;(2007).&#32;"Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study". <it>Neuropsychopharmacology</it>&#32;<b>33</b>: 1259. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1038%2Fsj.npp.1301500">
10.1038/sj.npp.1301500</weblink>. PMID 17625501.</cite>&nbsp;</entry>
<entry id="3">
<weblink xlink:type="simple" xlink:href="http://www.jnj.com/news/jnj_news/20051026_164127.htm">
News – Johnson &amp; Johnson</weblink></entry>
</reflist>
</p>

</sec>
<sec>
<st>
External links</st>
<p>

<list>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://pehomepage.com/Treating-PE/Medications/Treatment_for_premature_ejaculation_Interview_with_Lead_Investigator_for_Dapoxetine_(_Priligy_™_)_77.html">
"PEhomepage.com - treatments for premature ejaculation"</weblink> - an article on dapoxetine</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.webmd.com/content/article/127/116615.htm">
"Premature Ejaculation Drug Promising"</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.msnbc.msn.com/id/8478505/">
"The many mysteries of the female orgasm"</weblink> - An editorial about advances in sexual pharmacology</entry>
</list>
</p>




</sec>
</bdy>
</article>
